The University of Maryland School of Medicine Enters Research Collaboration with BioMark Diagnostics

Vancouver, British Columbia – (June 26, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that BioMark and the University of Maryland School of Medicine (UMSOM) have entered into a collaboration related to the discovery and validation of biomarkers using a combinatorial technology approach. This collaboration follows several productive meetings between BioMark and UMSOM clinicians and lab service specialists as well as employees in UMSOM’s offices of technology transfer, research affairs, and research and development.

 

The initial primary area of focus will be to confirm through a proof of concept study the clinical utility of using tumour biomarker(s) developed by BioMark initially in accelerating assessment following glioblastoma multiforme (GBM) resection and correlating it to existing anatomical imaging tests for confirmation. Drs Graeme Woodworth -Professor, Department of Neurosurgery, Director, Brain Tumor Treatment and Research Center Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine) and Chetan Bettegowda – Associate Professor of Neurosurgery and Oncology and Director of Meningioma Centre Department of Neurosurgery Johns Hopkins will be principal investigators (PIs) on this study. The study will commence after ethics approval is granted. A Canadian team will also be conducting a parallel and augmenting study at the University of Manitoba and CancerCare Manitoba sites under the CHRP grant received in April 2019.

 

A second area of focus will be an assay validation of BioMark’s lung cancer liquid biopsy for utilization in early lung cancer screening initiatives and measuring response to treatment. Dr. Christian Rolfo (Professor at the Department of Medicine at the University of Maryland School of Medicine, Director, Thoracic Medical Oncology, and Director, Early Phase Clinical Trials at University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center) will be the PI leading most of the studies (prospective, retrospective and longitudinal) related to lung cancer.

 

“BioMark is excited to collaborate with the University of Maryland School of Medicine and to be part of Maryland’s dynamic medical technology ecosystem. This is a significant opportunity and moment for our company,” said Rashid Ahmed, CEO of BioMark. “In addition, BioMark is planning to set up operations in Baltimore, and the current designated site is located at 875 Hollins Street Suite 102-G Baltimore MD 21201. More details will be released as planned progress is made.”

 

 

About the University of Maryland School of Medicine

 

The University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It is dedicated to providing excellence in biomedical education, basic and clinical research, quality patient care and service to improve the health of the citizens of Maryland and beyond. UMSOM is committed to the education and training of medical, MD/PhD, graduate, physical therapy and medical and research technology students. The university recruits and develops faculty to serve as exemplary role models for their students.

 

World Class Research

UMSOM is one of the fastest growing, top-tier biomedical research enterprises in the world. It has 43 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine, and a distinguished recipient of the Albert E. Lasker Award in Medical Research.

 

The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally with research and treatment facilities in 36 countries.

 

Compassionate Patient-Centered Care

With an operating budget of more than $1 billion, UMSOM works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year.

 

Educational Excellence

UMSOM has over 2,500 students, residents, and fellows, and nearly $450 million in extramural funding, with more than half of its academic departments ranked in the top 20 among all public medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has nearly 7,000 total employees.

 

Economic Impact

The combined School and Medical System (“University of Maryland Medicine”) has a total budget of $5 billion and an economic impact of nearly $15 billion on the state and local community.

 

Further information about University of Maryland School of Medicine is available under its official website: https://www.medschool.umaryland.edu/

News Release – The University of Maryland School of Medicine Enters Research Collaboration with BioMark Diagnostics

BioMark Announces Debt Settlement

Vancouver, British Columbia – (June 18th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that it has arranged a voluntary debt to share settlement (the “Debt Settlement”) with certain directors and officers of the Company in connection with existing indebtedness related to services provided to the Company by such directors and officers (and for which amounts had accrued as reflected in the Company’s financial statements but which had not been paid).

 

Pursuant to the Debt Settlement, the Company will issue a total of 1,000,000 common shares (the “Debt Shares”) at a deemed price of $0.15 per Debt Share in settlement of the indebtedness in aggregate amount of $150,000. No Warrants were issued in connection with the debt settlement.

 

Rashid Ahmed, CEO of BioMark commented, “We have chosen to increase our equity stake in BioMark as a show of confidence in our future. We are witnessing increased interest in the science and potential of metabolomics from both the medical and investment communities. As one of the leaders in metabolomics research and cancer diagnostics, we remain confident that our science and technology can have a significant impact on the lives of many people. In addition, The Company is choosing to settle the indebtedness through the issuance of Shares to preserve cash and improve the Company’s balance sheet as it enters a new and exciting phase of growth.”

 

The issuance of the Debt Shares will not result in the creation of any new control person.  The Debt Shares will be subject to a four month plus 1 day hold period.

 

The above transaction contemplates a related party transaction as Debt Shares will be issued to directors and officers of the Company.  The Company is relying on an exemption from minority shareholder approval under Multilateral Instrument 61-101 on the basis that participation by insiders does not exceed 25% of the fair market value of the Company’s market capitalization.

News Release – BioMark Announces Debt Settlement

BIOMARK ANNOUNCES NEW PATENT GRANTED IN UNITED STATES

Vancouver, British Columbia – (May 30th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been recently granted in United States.

 

Rashid Ahmed, President and CEO, says, “Granting of this patent expands and strengthens our metabolite measurement capabilities by offering options to cost effectively and reliably quantify the substrate of interest (acetylamantadine) in a biological sample for our SSAT1 urine-based assay using Raman spectroscopy. This technology can be used in economically and resource challenged environments on a global basis once the SSAT1 assay is approved by regulators. More positive patent news is anticipated in the near future. We remain optimistic that adding critical patents would enhance the commercial value of BioMark’s technology platform.”

 

Press Release – BIOMARK ANNOUNCES NEW PATENT GRANTED IN USA

REVISION ON TOTAL FUNDING SECURED BY BIOMARK AND ITS TEAM OF COLLABORATORS ON CHRP APPLICATION

Vancouver, British Columbia – (May 1st, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) would like to correct its  news release dated on  April 17th, 2019 announcing the approval of  the application entitled “Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma”, submitted to the Collaborative Health Research Projects funding opportunity.  The application was Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) and in collaboration with the Social Sciences and Humanities Research Council (SSHRC). The correct funding amount is $750,000 and not $400,000 over 3 years. BioMark is the industrial partner on the grant.

 

“The company during the time of the announcement factored only the funds provided by CIHR and not the matching portion from Natural Sciences and Engineering Research Council of Canada (NSERC) says, Rashid Ahmed, President and CEO. We apologize for the error and BioMark again would like to acknowledge CIHR, NSERC and SSHRC for the funding.

 

About CHRP

Collaborative Health Research Projects (CHRP) is a joint initiative between the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Social Sciences and Humanities Research Council of Canada (SSHRC). CHRP grants support focused, interdisciplinary, collaborative research projects involving any field of the natural sciences or engineering and any field of the health sciences.

Proposed research projects should be innovative, with a strong focus on knowledge translation, and lead to health benefits for Canadians, more effective health services and/or economic development in health-related areas.

Press Release – REVISION ON TOTAL FUNDING SECURED BY BIOMARK AND ITS TEAM OF COLLABORATORS ON CHRP APPLICATION